Brief: Bicycle Therapeutics Says Cash Position Of $293.8 Million At March 31, Excludes $50 Million Upfront Payment From Novartis, Expected To Provide Financial Runway Into 2025
May 4 (Reuters) - Bicycle Therapeutics PLC BCYC.O :
* BICYCLE THERAPEUTICS - CASH POSITION OF $293.8 MILLION AT
MARCH
31, EXCLUDES $50 MILLION UPFRONT PAYMENT FROM NOVARTIS, EXPECTED
TO PROVIDE FINANCIAL RUNWAY INTO 2025
* QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $1.30
* Q1 EARNINGS PER SHARE VIEW $-1.07 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBw2q0t4Ba
Further company coverage: BCYC.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Bicycle Therapeutics
See all newsBicycle Therapeutics PLC reports results for the quarter ended September 30 - Earnings Summary
UK's Bicycle Therapeutics Q3 loss narrows as expenses fall
Bicycle Therapeutics PLC expected to post a loss of 43 cents a share - Earnings Preview
UK's Bicycle Therapeutics Q2 net loss narrows on reduced clinical program expenses
Bicycle Therapeutics Q1 revenue drops after partnership terminations